Marta Zwart
Autonomous University of Barcelona
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marta Zwart.
BMC Musculoskeletal Disorders | 2011
Rafael Azagra; Genís Roca; Gloria Encabo; Daniel Prieto; Amada Aguyé; Marta Zwart; Sílvia Güell; Núria Puchol; Emili Gené; Enrique Casado; Pilar Sancho; Silvia Solà; Pere Torán; Milagros Iglesias; Victòria Sabaté; Francesc López-Expósito; Sergio Ortiz; Yolanda Fernandez; Adolf Díez-Pérez
BackgroundAge-related bone loss is asymptomatic, and the morbidity of osteoporosis is secondary to the fractures that occur. Common sites of fracture include the spine, hip, forearm and proximal humerus. Fractures at the hip incur the greatest morbidity and mortality and give rise to the highest direct costs for health services. Their incidence increases exponentially with age.Independently changes in population demography, the age - and sex- specific incidence of osteoporotic fractures appears to be increasing in developing and developed countries. This could mean more than double the expected burden of osteoporotic fractures in the next 50 years.Methods/DesignTo assess the predictive power of the WHO FRAX™ tool to identify the subjects with the highest absolute risk of fragility fracture at 10 years in a Spanish population, a predictive validation study of the tool will be carried out. For this purpose, the participants recruited by 1999 will be assessed. These were referred to scan-DXA Department from primary healthcare centres, non hospital and hospital consultations. Study population: Patients attended in the national health services integrated into a FRIDEX cohort with at least one Dual-energy X-ray absorptiometry (DXA) measurement and one extensive questionnaire related to fracture risk factors. Measurements: At baseline bone mineral density measurement using DXA, clinical fracture risk factors questionnaire, dietary calcium intake assessment, history of previous fractures, and related drugs. Follow up by telephone interview to know fragility fractures in the 10 years with verification in electronic medical records and also to know the number of falls in the last year. The absolute risk of fracture will be estimated using the FRAX™ tool from the official web site.DiscussionSince more than 10 years ago numerous publications have recognised the importance of other risk factors for new osteoporotic fractures in addition to low BMD. The extension of a method for calculating the risk (probability) of fractures using the FRAX™ tool is foreseeable in Spain and this would justify a study such as this to allow the necessary adjustments in calibration of the parameters included in the logarithmic formula constituted by FRAX™.
BMC Musculoskeletal Disorders | 2012
Rafael Azagra; Genís Roca; Gloria Encabo; Amada Aguyé; Marta Zwart; Sílvia Güell; Núria Puchol; Emili Gené; Enrique Casado; Pilar Sancho; Silvia Solà; Pere Torán; Milagros Iglesias; Maria Carmen Gisbert; Francesc López-Expósito; Jesús Pujol-Salud; Yolanda Fernandez-Hermida; Ana Puente; Mireia Rosàs; Vicente Bou; Juan José Antón; Gustavo Lansdberg; Juan Carlos Martín-Sánchez; Adolf Díez-Pérez; Daniel Prieto-Alhambra
BackgroundThe WHO has recently published the FRAX® tool to determine the absolute risk of osteoporotic fracture at 10 years. This tool has not yet been validated in Spain.Methods/designA prospective observational study was undertaken in women in the FRIDEX cohort (Barcelona) not receiving bone active drugs at baseline. Baseline measurements: known risk factors including those of FRAX® and a DXA. Follow up data on self-reported incident major fractures (hip, spine, humerus and wrist) and verified against patient records. The calculation of absolute risk of major fracture and hip fracture was by FRAX® website. This work follows the guidelines of the STROBE initiative for cohort studies. The discriminative capacity of FRAX® was analyzed by the Area Under Curve (AUC), Receiver Operating Characteristics (ROC) and the Hosmer-Lemeshow goodness-of-fit test. The predictive capacity was determined using the ratio of observed fractures/expected fractures by FRAX® (ObsFx/ExpFx).ResultsThe study subjects were 770 women from 40 to 90 years of age in the FRIDEX cohort. The mean age was 56.8 ± 8 years. The fractures were determined by structured telephone questionnaire and subsequent testing in medical records at 10 years. Sixty-five (8.4%) women presented major fractures (17 hip fractures). Women with fractures were older, had more previous fractures, more cases of rheumatoid arthritis and also more osteoporosis on the baseline DXA. The AUC ROC of FRAX® for major fracture without bone mineral density (BMD) was 0.693 (CI 95%; 0.622-0.763), with T-score of femoral neck (FN) 0.716 (CI 95%; 0.646-0.786), being 0.888 (CI 95%; 0.824-0.952) and 0.849 (CI 95%; 0.737-0.962), respectively for hip fracture. In the model with BMD alone was 0.661 (CI 95%; 0.583-0.739) and 0.779 (CI 95%; 0.631-0.929). In the model with age alone was 0.668 (CI 95%; 0.603-0.733) and 0.882 (CI 95%; 0.832-0.936). In both cases there are not significant differences against FRAX® model. The overall predictive value for major fracture by ObsFx/ExpFx ratio was 2.4 and 2.8 for hip fracture without BMD. With BMD was 2.2 and 2.3 respectively. Sensitivity of the four was always less than 50%. The Hosmer-Lemeshow test showed a good correlation only after calibration with ObsFx/ExpFx ratio.ConclusionsThe current version of FRAX® for Spanish women without BMD analzsed by the AUC ROC demonstrate a poor discriminative capacity to predict major fractures but a good discriminative capacity for hip fractures. Its predictive capacity does not adjust well because leading to underdiagnosis for both predictions major and hip fractures. Simple models based only on age or BMD alone similarly predicted that more complex FRAX® models.
Medicina Clinica | 2015
Rafael Azagra; Genís Roca; Juan Carlos Martín-Sánchez; Enrique Casado; Gloria Encabo; Marta Zwart; Amada Aguyé; Adolf Díez-Pérez
BACKGROUND AND OBJECTIVE To detect FRAX(®) threshold levels that identify groups of the population that are at high/low risk of osteoporotic fracture in the Spanish female population using a cost-effective assessment. PATIENTS AND METHODS This is a cohort study. Eight hundred and sixteen women 40-90 years old selected from the FRIDEX cohort with densitometry and risk factors for fracture at baseline who received no treatment for osteoporosis during the 10 year follow-up period and were stratified into 3 groups/levels of fracture risk (low<10%, 10-20% intermediate and high>20%) according to the real fracture incidence. RESULTS The thresholds of FRAX(®) baseline for major osteoporotic fracture were: low risk<5; intermediate ≥ 5 to <7.5 and high ≥ 7.5. The incidence of fracture with these values was: low risk (3.6%; 95% CI 2.2-5.9), intermediate risk (13.7%; 95% CI 7.1-24.2) and high risk (21.4%; 95% CI12.9-33.2). The most cost-effective option was to refer to dual energy X-ray absorptiometry (DXA-scan) for FRAX(®)≥ 5 (Intermediate and high risk) to reclassify by FRAX(®) with DXA-scan at high/low risk. These thresholds select 17.5% of women for DXA-scan and 10% for treatment. With these thresholds of FRAX(®), compared with the strategy of opportunistic case finding isolated risk factors, would improve the predictive parameters and reduce 82.5% the DXA-scan, 35.4% osteoporosis prescriptions and 28.7% cost to detect the same number of women who suffer fractures. CONCLUSIONS The use of FRAX ® thresholds identified as high/low risk of osteoporotic fracture in this calibration (FRIDEX model) improve predictive parameters in Spanish women and in a more cost-effective than the traditional model based on the T-score ≤ -2.5 of DXA scan.
BMC Public Health | 2011
Marta Zwart; Rafael Azagra; Gloria Encabo; Amada Aguyé; Genís Roca; Sílvia Güell; Núria Puchol; Emili Gené; Francesc López-Expósito; Silvia Solà; Sergio Ortiz; Pilar Sancho; Liz Abado; Milagros Iglesias; Jesús Pujol-Salud; Adolf Díez-Pérez
BackgroundOsteoporosis is a serious health problem that worsens the quality of life and the survival rate of individuals with this disease on account the osteoporotic fractures. Studies have long focused on women, and its presence in men has been underestimated. While many studies conducted in different countries mainly assess health-related quality of life and identify fracture risks factors in women, few data are available on a Spanish male population.Methods/DesignObservational study.Study populationMen ≥ 40 years of age with/without diagnosed osteoporosis and with/without osteoporotic fracture included by their family doctor.MeasurementsThe relationship between customary clinical risk factors for osteoporotic fracture and health-related quality of life in a Spanish male population. A telephone questionnaire on health-related quality of life is made.Statistical analysisThe association between qualitative variables will be assessed by the Chi-square test. The distribution of quantitative variables by Students t-test. If the conditions for using this test are not met, the non-parametric Mann-Whitneys U test will be used.The validation of the results obtained by the FRAX™ tool will be performed by way of the Hosmer-Lemeshow test and by calculating the area under the Receiver Operating Characteristic (ROC) curve (AUC). All tests will be performed with a confidence intervals set at 95%.DiscussionThe applicability and usefulness of Health-related quality of life (HRQOL) studies are well documented in many countries. These studies allow implementing cost-effective measures in cases of a given disease and reducing the costly consequences derived therefrom. This study attempts to provide objective data on how quality of life is affected by the clinical aspects involved in osteoporosis in a Spanish male population and can be useful as well in cost utility analyses conducted by health authorities.The sample selected is not based on a high fracture risk group. Rather, it is composed of men in the general population, and accordingly comparisons should not lead to erroneous interpretations.A possible bias correction will be ensured by checking reported fractures against healthcare reports and X-rays, or by consulting health care centers as applicable.
Medicina Clinica | 2015
Rafael Azagra; Genís Roca; Juan Carlos Martín-Sánchez; Enrique Casado; Gloria Encabo; Marta Zwart; Amada Aguyé; Adolf Díez-Pérez
Atencion Primaria | 2012
Rafael Azagra; Marta Zwart; Amada Aguyé; Gloria Encabo
Medicina Clinica | 2015
Rafael Azagra; Francisco López-Expósito; Juan Carlos Martín-Sánchez; Amada Aguyé-Batista; Paula Gabriel-Escoda; Marta Zwart; Miguel Angel Díaz-Herrera; Jesús Pujol-Salud; Milagros Iglesias-Martínez; Núria Puchol-Ruiz
Medicina Clinica | 2011
Rafael Azagra; Genís Roca; Marta Zwart; Gloria Encabo
Medicina Clinica | 2011
Rafael Azagra; Genís Roca; Marta Zwart; Gloria Encabo
Maturitas | 2016
Rafael Azagra; Marta Zwart; Amada Aguyé; Juan Carlos Martín-Sánchez; Enrique Casado; Miguel Angel Díaz-Herrera; David Moriña; C Cooper; A Diez-Perez; Elaine M. Dennison